BioVersys will receive €20 million in funding to support its development of new treatments for antimicrobial resistant infections.
List view / Grid view
Filter the results
The Garnet™ therapeutic product, which can capture more than 100 clinically relevant bacteria, fungi, parasites, toxins and viruses from the blood, will soon begin clinical testing.
The international Phase III trial will evaluate whether a 14 day course of carrimycin can improve outcomes for COVID-19 patients with severe symptoms.
Therapyx and Intravacc will jointly develop NGoXIM, a microsphere vaccine which is designed to stimulate adaptive immunity against gonorrhoea.
The company announced the voluntary recall is due to low, out of specification dissolution test results in specific batches of its tetracycline products.
A study of both city and rural water sources identified antimicrobials at every site and suggests the contamination could be causing the emergence of treatment-resistant microbes.
Drug Target Review rounds up some of the latest developments in materials developed for medical applications, including hydrogels, implants and more.
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
A WHO review has concluded that while innovative therapies have been developed for TB and C. diff, other priority pathogens are likely to develop resistance to future therapies.
Research has developed bandages which change colour and release antibiotics and/or reactive oxygen species in response to an infected wound which could curb the spread of antibiotic resistance.